Breast Cancer:

• sample material: whole blood/serum/plasma
• rapid results in as little as 10 minutes
• sensitivity: 96.4%, specificity: 98.8%, accuracy: 98.3%
• single packaging
• high-quality product
• intended for professional use
• the package includes a test cassette, sterile lancet, buffer, dropper, disinfectant wipe, and instruction manual.

Test Applications

Our test is an ideal solution for professionals across various fields, especially internists, gynecologists, and oncologists, and can be useful in:

• Early-stage cancer diagnosis: CA15-3 tests can help detect breast cancer in its early stages, enabling faster intervention and more effective treatment.
• Treatment monitoring: CA15-3 tests allow for tracking the effectiveness of therapy in breast cancer patients, enabling doctors to assess treatment response and make adjustments if necessary.
• Detecting recurrences: Following breast cancer treatment, there is a risk of recurrence. CA15-3 tests allow for the early detection of potential recurrences, enabling prompt action.
• Screening: CA15-3 tests can be used as part of screening programs in populations at increased risk of breast cancer, facilitating early detection of potential cases.

Gastrointestinal Cancer:

• sample material: whole blood/serum/plasma
• rapid results in as little as 10 minutes
• sensitivity: 96.9%, specificity: 98.7%, accuracy: 98.3%
• single packaging
• high-quality product
• intended for professional use
• the package includes a test cassette, sterile lancet, buffer, dropper, disinfectant wipe, and instruction manual

Test Applications:

Our test is an excellent tool for professionals such as gastroenterologists, internists, and oncologists, assisting in:

• Early-stage cancer diagnosis: CA19-9 tests can be part of the diagnostic process for early-stage pancreatic and colorectal cancer, allowing for quicker disease identification and improving treatment success rates.
• Monitoring therapy effectiveness: CA19-9 tests help physicians track a patient’s response to cancer treatment. A decrease in antigen levels may indicate a positive response, while an increase might suggest recurrence or resistance to therapy.
• Detecting recurrences: After cancer treatment, there is a risk of recurrence. Regular monitoring of CA19-9 levels helps detect disease recurrence early, enabling timely therapeutic action.
• Healthcare planning: CA19-9 tests can aid in creating healthcare plans for patients with pancreatic or colorectal cancer. Test results guide physicians in tailoring therapy and monitoring disease progression.
• Screening: In certain cases, CA19-9 tests can be used in screening high-risk patients, such as those with a family history of cancer or other risk factors.